Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIA: Ribociclib vs Palbociclib in Advanced HR+/HER2- Breast Cancer
NCT05207709Phase 3Terminated
- Sponsor
- SOLTI
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by SOLTI. Started Mar 2022; status: terminated.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05207709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207709.